RxDoctor Payments Data

Ryan McHugh, MD

Interventional Pain Medicine · Nederland, TXNPI 1811976715

Payments from drug & device makers

$2,355in general payments, 2019–2025

Across 102 payments — averaging $23.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$360
  • Nevro Corp.$352
  • Biotronik NRO, Inc.$324
  • Medtronic$177
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$172
  • Arbor Pharmaceuticals, Inc.$141
  • plus $830 from 21 others

What the payments were for

  • Food & beverage$2,32099%
  • Education$351%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,355 in reported general payments places this provider in the 30th percentile of 287 interventional pain medicine providers in Texas.

See all interventional pain medicine providers in Texas

Medicare billing

Part B allowed, 2024
$207,019
Medicare patients
284
Services billed
2,917

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RelistorMethylnaltrexone Bromide95$224,199
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen4,861$133,730
Naloxone Hcl770$46,672
MovantikNaloxegol Oxalate118$45,993
Fentanyl86$12,408
Buprenorphine44$11,667
LyricaPregabalin13$11,093
Acetaminophen-CodeineAcetaminophen With Codeine621$10,802
Lidocaine104$10,465
BelbucaBuprenorphine Hcl16$10,449
Gabapentin968$8,935
Pregabalin402$7,653
Tizanidine Hcl1,188$7,366
Morphine Sulfate ErMorphine Sulfate221$5,420
Tramadol Hcl564$4,067

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$172$224,19995 claims
Redhill Biopharma Inc.Movantik$32$45,993118 claims
Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate$35$11,89262 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 287 interventional pain medicine providers in Texas.

Other interventional pain medicine in Nederland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →